Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term outcomes with single-agent BRAF-inhibitor therapy in Erdheim-Chester disease
    Meeting Abstract

    Goyal, G.; Reiner, A.; Bossert, D.; Sigler, A.; Buthorn, J.; Lacouture, M.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Precision lineage deconvolution in mixed phenotype acute leukemia using CITE-seq derived hematopoietic stages identifies lineage dynamics associated with treatment response
    Meeting Abstract

    Dilip, D.; Galera, P.; Nemirovsky, D.; Lallo, M.; Menghrajani, K.; Derkach, A.; Levine, R. L.; Koche, R.; Xiao, W.; Glass, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-cell acute lymphoblastic leukemia (R/R B-ALL): Pooled analysis of the ongoing FELIX phase Ib/II study
    Meeting Abstract

    Roddie, C.; Sandhu, K. S.; Tholouli, E.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Bishop, M. R.; Yared, J. A.; Ghobadi, A.; Yallop, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study
    Meeting Abstract

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular taxonomy of myelodysplastic syndromes and its clinical implications
    Meeting Abstract

    Bernard, E.; Hasserjian, R.; Greenberg, P. L.; Ossa, J. E. A.; Creignou, M.; Nannya, Y.; Tuechler, H.; Medina-Martínez, J. S.; Levine, M. F.; Jädersten, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; Pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study)
    Meeting Abstract

    Roddie, C.; Tholouli, E.; Shaughnessy, P.; Jabbour, E.; Logan, A. C.; Hodby, K.; Mountjoy, L.; Bloor, A. J. C.; Irvine, D.; Linch, D. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term follow up for SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Advani, A. S.; Moseley, A. B.; O'Dwyer, K. M.; Wood, B. L.; Park, J. H.; Wieduwilt, M. J.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients
    Meeting Abstract

    Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; McCloskey, J.; Takami, A.; Haque, T.; Ichii, M.; Shirane, S.; Fukaya, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - A large, multicenter, retrospective analysis from the validate database
    Meeting Abstract

    Bewersdof, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save